SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

BGT Bio-Gene Technology Limited

Healthcare · Biotechnology · website
$0.02
52wk 0.02 – 0.05
Overall
38.7
Value
74.0
Growth
0.0
Health
100.0
Quality
0.0
Momentum
0.0
Dividend
—
Price
About Bio-Gene Technology Limited

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University for experiments demonstrating the value of pre-conditioning biomass prior to distillation; Cesar for assessing the insecticidal activity of its molecules against a range of insect species; Advanced Molecular Technologies; CSIRO for a chemistry development process; the Department of Agriculture and Fisheries, Queensland Government for assessing activity against grain storage pests; Eurofins; Grain Research Development Corporation; Pacific Discovery Services; Purdue University; Southern Cross University for chemical analysis of natural products; University of Florida; and University of Technology. It serves animal health, crop protection, grain storage, public health, and consumer applications. The company was incorporated in 1995 and is based in Melbourne, Australia.

Price analytics

Returns

1 day 0.0%
1 week -5.9%
1 month -5.9%
3 months -5.9%
6 months -48.4%
1 year -54.3%
3 years -77.1%

Risk

Volatility (1y ann.) 87.7%
Beta vs ASX 200 -0.45
Sharpe (1y) -0.50
VaR 95% (1-day) -9.1%
Max drawdown (1y) -61.9%
Off 1-year high -61.9%

Technicals

RSI(14) 40
vs 50DMA -14.2%
vs 200DMA -38.4%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 74.0
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
67
Price / Sales
38
Growth 0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow) 0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 0.0
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
0

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$7.01M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.77
EV / EBITDA
-2.19
Price / Book
3.20
ROE
-125.4%
Operating margin
-86.9%
Net margin
-216.0%
Total cash
$1.94M
Total debt
$0
Current ratio
4.78
Debt / Equity
—
Free cash flow
$-1.12M
Avg volume
229,911
Latest annual results (FY ending 30 Jun 2026)
  • Revenue—
  • Gross profit—
  • Operating income-$3.41M
  • Net income-$2.33M
  • Diluted EPS—
  • Free cash flow-$1.94M
  • Net debt-$1.94M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4